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Abstract  21 
 22 
Five isoforms of follistatin (FST) (Mr 31, 33, 35, 37, 41kDa) were purified from bovine 23 
follicular fluid (bFF). Comparison of their activin- and heparan sulphate proteoglycan (HSP)-24 
binding properties and bio-potencies in neutralization of activin-A action in vitro revealed that 25 
all five isoforms bound activin-A, but with different affinities. Only the 31kDa isoform (FST-26 
288) bound to HSP.  FST-288 also showed the greatest biopotency with 35 and 41kDa 27 
isoforms being least potent. To determine whether bovine follicle development is associated 28 
with changing intrafollicular FST and activin profiles, we analyzed bFF from dominant (DF) 29 
and subordinate (SF) follicles collected at strategic times during a synchronized estrous cycle. 30 
Total FST, activin-A and activin-AB were measured by immunoassay while individual FST 31 
isoforms were quantified by immunoblotting. Follicle diameter was positively correlated with 32 
estrogen:progesterone ratio (r=0.56) in bFF but negatively correlated with activin-A (r=-0.34), 33 
activin-AB (r=-0.80) and ‘total’ FST (r=-0.70) levels.  Follicle diameter was positively 34 
correlated with abundance of the 41 kDa isoform (r=0.59) but negatively correlated with 35 
abundance of 33 and 31 kDa isoforms (r=-0.56, -0.41). Both follicle status (DF vs SF) and 36 
cycle stage affected total FST, activin-A, activin-B levels while follicle status, but not cycle 37 
stage, affected abundance of 41, 37, 33 and 31kDa FST isoforms. Collectively, these findings 38 
indicate that intrafollicular FST isoforms that differ in their ability to bind and neutralise 39 
activins and associate with cell-surface proteoglycans, show divergent changes during follicle 40 
development. Enhanced FST production may have an important negative role, either directly 41 
or via inhibition of the positive effects of activins, on follicle growth and function during 42 
follicular waves. 43 
 44 
 45 
 46 
Introduction 47 
 48 
Since the discovery and characterization of inhibins and activins over 25 years ago, numerous 49 
studies have investigated the involvement of these structurally-related yet reciprocally-acting 50 
proteins in the regulation of ovarian function (reviews:(Woodruff & Mather 1995, Knight & 51 
Glister 2001, Findlay et al. 2002, Phillips 2005, Knight et al. 2012). Regulatory roles 52 
impacting on follicle development are manifest both at the anterior pituitary (i.e. modulation 53 
of FSH secretion) and intraovarian level, with activin exerting local autocrine/paracrine 54 
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stimulatory effects that are opposed by inhibin and/or the activin-binding protein, follistatin 55 
(FST). For instance, in vitro studies have implicated activin as an important promoter of 56 
follicle growth/survival by virtue of its ability to upregulate cell proliferation, FSH receptor 57 
expression and enhance basal and FSH-induced oestrogen production by granulosa cells 58 
whilst simultaneously inhibiting progesterone production. In addition, activin suppresses LH-59 
induced androgen production by theca cells. The above actions can be reversed by inhibin 60 
and/or FST. Inhibin antagonises activin signalling by competitive binding to the type 2 activin 61 
receptor on the cell surface while follistatin (FST) inhibits activin signalling by acting as a 62 
high affinity activin-binding protein (de Winter et al. 1996, Schneyer et al. 1997, Sugino et al. 63 
1997, Harrison et al. 2006). 64 
 65 
FST is a cysteine-rich, monomeric glycoprotein, encoded by a single gene that is highly 66 
conserved amongst vertebrates(Schneyer et al. 1997, Sugino et al. 1997, Hedger & de Kretser 67 
2013). FST was first isolated from ovarian follicular fluid based on its activity to suppress 68 
FSH secretion by pituitary cells (Robertson et al. 1987). Multiple isoforms of FST protein 69 
exist, with up to six different isoforms identified in ovarian follicular fluid (Sugino et al. 70 
1997, Glister et al. 2006). These are generated by alternate mRNA splicing to yield two core 71 
proteins (FST-288 and FST-315). FST-315 can undergo posttranslational cleavage of the 72 
carboxy-terminal sequence to yield FST-303. These three ‘core’ proteins can also be 73 
glycosylated to produce the six isoforms identified in porcine (Sugino et al. 1993, Sugino et 74 
al. 1997) and bovine (Glister et al. 2006) follicular fluid. It has previously been reported that 75 
FST can bind to heparan-sulphate proteoglycans (HSP) on the surface of granulosa and other 76 
cells with the shorter (FST-288) forms binding with much higher affinity than the longer 77 
(FST-315) forms, implying different roles in modulating activin function (Nakamura et al. 78 
1991, Nakamura et al. 1997). Moreover, binding of FST-activin complexes to cell surface 79 
proteoglycans facilitates endocytosis and their subsequent lysosomal degradation (Hashimoto 80 
et al. 1997). In addition to their recognised roles in reproductive tissues, activins and FST are 81 
important regulators of haematopoiesis, immunoregulation, inflammation, wound healing and 82 
fibrosis (review: (Hedger & de Kretser 2013)). 83 
 84 
With regard to previous studies on the ovarian inhibin-activin-FST system in various species, 85 
an important caveat is that a large majority has been carried out using just one FST form 86 
(recombinant human (rh)FST-288) and one activin form (rh activin-A), both of which have 87 
been widely available to the research community primarily from commercial sources. In 88 
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addition, very little information is available on the relative abundance of individual isoforms 89 
of FST and activin in different biological compartments including ovarian follicular fluid. 90 
With this in mind, the primary objective of the present study was to purify native FST 91 
isoforms from pooled bovine follicular fluid allowing a direct comparison of their activin- and 92 
heparan sulphate-binding properties as well as their bio-potencies in reversing the inhibitory 93 
effect of activin-A on thecal androgen production in vitro. In addition, we used quantitative 94 
immuno-analytical techniques (ELISA, western blotting) to test the hypothesis that post-95 
emergence antral follicle growth in estrous cycle-synchronised cattle is associated with 96 
changing intrafollicular levels of different isoforms of FST and activin, reflecting differential 97 
production and roles of these proteins in follicle selection and dominance in this 98 
monovulatory species.  99 
 100 
 101 
Materials and Methods 102 
 103 
Purification of FST isoforms from pooled bFF 104 
 105 
Pooled bovine follicular fluid (bFF; protein content 65mg/ml) was collected by needle 106 
aspiration of non-cystic follicles visible on the surface of cattle ovaries obtained from the 107 
slaughterhouse. bFF was stored at -80
o
C in the presence of a protease inhibitor (0.005% w/v 108 
phenylmethylsulphonylfluoride, PMSF). After thawing, bFF was centrifuged (20,000g, 109 
30min, 4
o
C) and the supernatant (200ml) applied to an anti-FST immunoaffinity column. This 110 
was prepared by coupling 10mg of a 1:1 mixture of two anti-FST monoclonal antibodies 111 
(MAb; clones FST 1/1 and 8/1; gift from Prof NP Groome) to 5ml of n-hydroxysuccinamide-112 
activated sepharose beads (GE Healthcare Ltd), according to the manufacturer’s instructions.  113 
bFF (200ml; 13g protein) was cycled through the anti-FST immunoaffinity column at a flow 114 
rate of 0.5 ml/min, overnight at 4
o
C. After washing the column with 100ml PBS the bound 115 
fraction (containing multiple FST isoforms as well as activins bound to FST) was eluted using 116 
3 column volumes (15 ml) of 8M urea. Urea solution was deionised by passing it through a 117 
mixed bed ion exchange resin (Monobed, Amberlite) immediately before use.  After 118 
immunoaffinity chromatography, subsequent steps used to isolate the FST isoforms were 119 
based upon the method described by Sugino et al. (Sugino et al. 1993) with some 120 
modifications. CHAPS (0.05% w/v final) and TRIS-HCl pH 7.8 pre-set crystals (20mM final) 121 
were added to the fraction eluted from the immunoaffinity column and it was applied to a fast 122 
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protein liquid chromatography (FPLC) Mono P anion exchange column (5 x 100 mm; 123 
Pharmacia Ltd), pre-equilibrated with 20mM Tris-HCl pH 7.8 and 0.05% w/v CHAPS. Four 124 
distinct peaks (A, B, C and D) were eluted with a linear gradient from 0 to 1M NaCl in 20mM 125 
Tris/HCl (pH 7.8) at a flow rate of 1ml/min over 40 minutes, with 0.5 min fractions collected. 126 
Pooled fractions comprising each peak, plus the non-retained (NR) fraction, were further 127 
purified by reversed phase HPLC using a Cosmosil C8 (4.6 x 150mm) column. The column 128 
was developed with a 5min linear gradient of 10-30% acetonitrile in 0.1% trifluoroacetic acid 129 
(TFA), followed by a 10min gradient of 30-40% at a flow rate of 1ml/min with fraction 130 
collected every 0.25 min. Highly enriched FST-containing fractions were designated as RP-131 
HPLC peaks #1, #2, #3, #4 and #5.Throughout the purification procedure chromatographic 132 
eluates were monitored for UV absorbance at 280nm. Fractions were also analysed for FST 133 
immunoreactivity using a two-site ELISA (see below). Estimates of total protein 134 
concentrations and final yields were based on the assumption that a 1mg/ml solution of 135 
protein has a 280nm absorbance value of 1.0.  136 
 137 
 138 
 Deglycosylation of purified FST isoforms 139 
 140 
A 1g aliquot each of the purified FST isoforms was treated with a mixture of five different 141 
deglycosylation enzymes (E-DEGLY kit; Sigma) according to the manufacturer’s 142 
instructions. Treated versus non-treated samples were run on SDS-PAGE and stained with 143 
silver nitrate according to the method of (Morrissey 1981).  144 
 145 
 146 
SDS-PAGE and Western Blotting 147 
 148 
Purified bovine FST fractions and bFF samples harvested from cycle-synchronized heifers 149 
(see below) were analysed by SDS-PAGE/Western blotting as described previously (Glister et 150 
al 2006). SDS-PAGE was performed under non-reducing conditions using 12.5% gels. Gels 151 
were either stained with Coomassie blue to detect total proteins or subjected to electrophoretic 152 
transfer to nitrocellulose membranes for immunodetection of individual FST isoforms using a 153 
1:1 mixture of FST MAb (clone 1/1 and clone 8/1). 
125
I-labelled horse anti-mouse IgG was 154 
used as secondary antibody to detect membrane-bound anti-FST MAb using a phosphor 155 
screen and Phosphorimager (Molecular Dynamics) and images were analysed using Image J 156 
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(v1.32J) software. The between-gel coefficient of variation for FST band intensity averaged 157 
10.6%, based on estimates for a pooled bFF quality control sample included on each gel.  158 
 159 
 160 
Bioassay for FST isoform activity 161 
 162 
The biological potency of each purified bovine FST isoform, along with that of recombinant 163 
human (rh) FST-288 (R&D Systems, UK), was determined using an in vitro bovine theca cell 164 
bioassay based upon the ability of FST to block the suppressive effect of activin on 165 
androstenedione production by LH-treated theca cells. Bovine theca cells were isolated and 166 
cultured as described previously (Glister et al. 2005). The cells were cultured under serum-167 
free conditions for 6 days with media changed and treatments, including LH (150pg/ml), 168 
added on day 2 and 4. Before addition to cells, FST and activin treatment combinations were 169 
diluted in culture medium and pre-incubated for 4h at room temperature to allow any FST-170 
activin association to occur. A near-maximally effective concentration of activin-A (10ng/ml 171 
giving ~85% suppression of androstenedione secretion) was used and the molar ratio of FST 172 
to activin-A was adjusted to 0:1, 2:1, 4:1, 8:1 or 16:1. Molar ratio, rather than mass ratio, was 173 
used to account for the differences in molecular mass amongst the different FST isoforms. At 174 
the end of the culture period conditioned media were removed and stored at -20
o
C until 175 
assayed for androstenedione; viable cell number was determined by neutral red dye uptake 176 
assay. Each experiment was repeated four times using independent batches of cells. 177 
 178 
 179 
Biacore surface plasmon resonance experiments to determine binding affinities 180 
 181 
To determine the binding affinity of purified FST isoforms for immobilised rh Activin-A and 182 
heparan sulphate proteoglycan (HSP), experiments were performed using the Biacore 3000 183 
surface plasmon resonance (SPR) instrument (Biacore International, Stevenage, Herts). rh 184 
Activin-A (R&D Systems) and HSP (Sigma) were immobilised on the surface of separate 185 
CM5 sensor chips (~500 resonance units) according to the manufacturer’s protocol (Biacore). 186 
BSA was immobilised on an adjacent lane of each chip (~500 resonance units) to act as 187 
independent controls for rh activin-A and HSP. Purified bovine FST isoforms and rhFST-288 188 
were passed over both chips at a flow rate of 30l/min. Hepes-buffered saline (10mM Hepes, 189 
150mM NaCl, 3.4 mM EDTA, 0.005% Tween20, pH 7.4) was used for sample dilution and as 190 
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a running buffer. Each FST isoform was run over immobilised rhAct-A, HSP and BSA lanes 191 
at a range of concentrations (6.25, 12.5, 18.75, 25, 37.5, 50, 75, 100 nmol/l). For chip 192 
regeneration bound FST was eluted from the rh activin-A or HSP coated surface using 50mM 193 
NaOH and 1M NaCl. Binding curves were corrected by subtraction of the blank and 194 
evaluated using Biacore evaluation software. Each experiment was repeated at least 3 times 195 
and kinetic data, including KD, were calculated using the Biacore evaluation software.  196 
 197 
 198 
Comparison of biological activities and FST binding properties of activins A, AB and B 199 
 200 
The ability of rh activin-A, activin-AB and activin B to suppress androstenedione secretion by 201 
bovine theca cells was compared by treating cells for 4 days with 0, 2, 10 and 50 ng/ml of 202 
each protein. The binding affinities of rh activin-A, activin-AB and activin B for immobilized 203 
rhFST-288 were evaluated by Biacore SPR analysis. Bioassay and binding experiments were 204 
repeated three times. 205 
 206 
 207 
Collection of ovarian samples from estrous cycle-synchronized cattle 208 
 209 
The bovine follicular fluid (bFF) samples analysed for activin and FST content in the present 210 
study were collected as part of a previous investigation focusing on analysis of inhibin and 211 
inhibin subunits (Sunderland et al. 1996). A detailed description of the animals and 212 
experimental procedures used to obtain the bFF samples, as well as their serum hormone 213 
profiles and bFF concentrations of inhibins, estradiol and progesterone can be found in the 214 
aforementioned publication. All animal work was carried out in accordance with regulations 215 
set down by the UCD BioMedical Centre, Dublin, Ireland, and by the Cruelty to Animals Act 216 
(Ireland). 217 
 218 
Briefly, estrous cycles of 28 crossbred beef heifers aged 15-18 months were synchronised 219 
using a 10-day progestagen implant regimen (Crestar: Intervet Ireland Ltd, Dublin) with 220 
PGF2 analogue (PG; Prosolvin: Intervet Ireland Ltd) administered two days prior to implant 221 
removal to initiate luteolysis. Follicular development was monitored by transrectal 222 
ultrasonography from the time of PG administration until approximately 12h before 223 
ovariectomy. Animals were allocated to one of five groups according to the time of 224 
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ovariectomy as follows: day 0 (follicular phase, pre-LH surge; n=5), day 1 (follicular phase, 225 
post-LH surge, pre-ovulation; n=6), day 3 (post-ovulation, selection phase; n=6), day 6 (post-226 
ovulation, dominance phase; n=5) and day 12 (post ovulation, atretic phase; n=6). 227 
 228 
Excised ovaries were placed in ice-cold PBS and the number of follicles ≥5mm and their 229 
diameters were recorded before bFF was aspirated from each follicle. The bFF samples were 230 
aliquotted and stored at -80˚C until analysis. For the present study follicles from each pair of 231 
ovaries were classified as the DF (largest or morphologically dominant follicle), SF1 (second 232 
largest or first subordinate follicle) or SF2p (bFF pooled from all remaining subordinate 233 
follicles ≥5mm). In addition, bFF concentrations of estradiol (E) and progesterone (P) were 234 
used to classify follicles as either estrogen active (EA; E/P ratio >1) or estrogen inactive (EI; 235 
E/P ratio < 1) (Ireland & Roche 1982).  236 
 237 
 238 
Hormone immunoassays 239 
 240 
Concentrations of androstenedione in theca cell-conditioned media were determined by 241 
radioimmunoassay (Glister et al. 2005). The detection limit of the assay was 50 pg/ml and the 242 
intra- and inter-assay CVs were 8 and 10% respectively. ‘Total’ (i.e free + activin-bound) 243 
FST levels in bFF samples and chromatographic fractions were determined by two-site 244 
ELISA (Tannetta et al. 1998). Values are expressed in terms of a rhFST preparation provided 245 
by Dr A Parlow (NHPP, USA). Assay sensitivity was 100pg/ml and intra- and inter-assay 246 
CVs were 7% and 9% respectively. ‘Total’ activin A concentrations in bFF were measured by 247 
two-site ELISA (Knight et al. 1996). Human recombinant (hr) Act-A (NIBSC, Potters Bar, 248 
Herts, UK) was used as a standard and the assay sensitivity was 100pg/ml. Intra- and inter-249 
assay CVs were 4% and 7% respectively. ‘Total’ activin-AB concentrations were measured 250 
using the two-site ELISA (Evans et al. 1997). The assay was calibrated using purified 251 
preparation of porcine activin-AB (gift from H Sugino) and had a sensitivity of 200pg/ml. 252 
Intra- and inter-plate CVs were 5% and 8% respectively. Activin-B concentrations were 253 
evaluated using a more recently developed 2-site ELISA (Ludlow et al. 2009). The assay was 254 
calibrated using hr Activin-B (R&D systems) and the sensitivity in this laboratory was about 255 
100 pg/ml. Intra- and inter-plate CVs were 9% and 12% respectively. 256 
 257 
 258 
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Statistical analysis 259 
 260 
Data from in vitro bioassays and Biacore experiments comparing different FST isoforms we 261 
isolated were evaluated using ANOVA and post-hoc Fisher’s PLSD test. One-way and two-262 
way ANOVA of log-transformed data were used to evaluate between-group differences in 263 
bFF levels of activin-A, activin-AB, ‘total’ FST and the proportion of ‘total’ FST represented 264 
by each of the six individual isoforms detected. Where indicated, post hoc Fishers PLSD test 265 
was subsequently used to make individual pair-wise comparisons. Linear correlation analyses 266 
were also used to examine the relationship between the above variables amongst the entire 267 
sample set. Unless stated otherwise, values are presented as arithmetic means ±SEM. 268 
 269 
 270 
Results 271 
 272 
Chromatographic purification of bovine ovarian FST isoforms 273 
 274 
Fig. 1 (lane 1) shows the presence of six different bands of FST immunoreactivity in pooled 275 
bFF (starting material). These bands had apparent molecular weights (Mr) ranging from 31-276 
65kDa. When FST was purified by affinity chromatography on an immobilised FST-MAb 277 
column, the eluate contained five Mr forms ranging from 31-41 kDa (fig.1, lane 2). When this 278 
material was applied to an anion exchange column (Mono P), five major regions of FST 279 
immunoreactivity (fig.1, lanes 3-7) were identified (using FST ELISA and Western blotting) 280 
corresponding to peaks A, B, C and D plus the non-retained fraction (NR) that passed straight 281 
through the column (fig. 2). Each of these five anion exchange fractions was further 282 
fractionated by reversed-phase HPLC to generate the final five highly purified FST isoforms 283 
(#1 - #5) shown in fig.1A lanes 8-12. The purity of each isoform was judged to be ≥74% 284 
based on densitometric analysis of FST immunoblots and ≥79% based on densitometric 285 
analysis of coomassie blue-stained gels (see Fig 1B and table 1). The purified FST 286 
preparations represent 8810-11475-fold purification factors and the final combined yield was 287 
17.7% (206g FST in total; 12-86g of each isoform) from 200ml of bFF starting material 288 
(see table 2). The amount of each FST isoform purified was quantified using a combination of 289 
ELISA (calibrated using rh FST-288), UV absorbance (280nm) and densitometric 290 
quantification of western blots using a calibration curve generated by running known amounts 291 
of hrFST-288 alongside the purified forms (see table 3). Relative to the rh FST-288 standard 292 
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(100%), cross reactivities of purified bovine isoforms #1 - #5 in the ELISA were 93, 86, 80, 293 
103 and 95%, respectively with each isoform yielding a parallel dilution curve. 294 
 295 
 296 
Characterisation of purified FST isoforms 297 
 298 
As it is known that potential Asn-linked glycosylation sites exist in FST proteins (Sugino et 299 
al, 1993) the purified proteins were treated with a mixture of deglycosylation enzymes, that 300 
included PNGase F which cleaves all asparagines-linked oligosaccharides, to ascertain 301 
whether the various forms were glycosylated variants of the core FST proteins. The multi-302 
glycosylated protein fetuin, included in the deglycosylation kit, served as a positive control; 303 
upon deglycosylation it ran as a smaller forms on SDS-PAGE (fig. 3 lanes 1 and 2). When 304 
enzyme-treated FST isoforms were electrophoresed under non-reducing conditions, #1, #2 305 
and #3 did not undergo a mobility shift, running at 31, 33 and 35 kDa respectively (fig.3 306 
lanes). Upon deglycosylation #5 underwent a mobility shift from 41 to 35 kDa (fig. 3 lanes). 307 
Unfortunately, insufficient amounts of #4 (apparent Mr 37 kDa) were available for inclusion 308 
in the deglycosylation experiment. Based on the size at which they ran on SDS-PAGE, we 309 
deduce from these observations that #1 is a non-glycosylated variant of core protein 288, #2 is 310 
the non-glycosylated variant of core protein 303, #3 is the non-glycosylated variant of core 311 
protein 315, with #5 appearing to be the glycosylated variant of core protein 315. 312 
 313 
 314 
Biological potencies of purified FST isoforms 315 
 316 
The biological properties of the five purified bovine FST forms, along with hr FST-288, were 317 
compared using an in vitro theca cell bioassay. As shown in fig.4, activin-A suppressed LH-318 
induced androstenedione secretion by ~85% (p<0.0001). Co-treatment of cells with FST dose-319 
dependently reversed the suppressive effect of activin on LH-induced androstenedione 320 
secretion. Each FST isoform neutralised activin-A bioactivity to a greater or lesser degree 321 
with ED50 values ranging from 1.7 fold to 4.4 fold molar excess of FST over activin (ED50 322 
data summarised in table 3). Bovine #1 (31kDa) had the same biopotency as hr FST-288 323 
(31kDa) from a commercial source (R&D systems). Conversely, #3 and #5 (35- and 41kDa 324 
respectively) had the lowest biopotencies of all forms tested (39% and 53% relative to hr 325 
FST-288 at 100%). In the absence of activin treatment (fig. 4B), none of the FST forms tested 326 
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had any significant effect on thecal cell androstenedione production consistent with the lack 327 
of endogenous activin production by these cells.  328 
 329 
 330 
Activin-binding properties of purified FST isoforms 331 
 332 
To investigate whether the differences observed between FST isoforms in neutralising activin 333 
bioactivity reflected different binding affinities of these FST forms for activin, the 334 
dissociation constant (KD) of each form for immobilised activin-A was quantified using 335 
Biacore (table 4). The KD was significantly greater for each of the larger FST isoforms (33, 336 
35, 37 and 41kDa) than for the smallest isoform #1 (31kDa) and hr FST-288, indicating lower 337 
affinity binding. The 35kDa and 41kDa isoforms formed the least stable complexes with 338 
activin-A, with KD values some 20-fold higher (~33nM) than for the 31kDa isoform (1.6nM). 339 
 340 
 341 
Heparan sulphate-binding properties of purified FST isoforms 342 
 343 
The differential ability of FST isoforms to bind to cell-surface heparin sulphate proteoglycans 344 
(HSP) has been implicated as a method whereby FST modulates the activity of activin in 345 
different extracellular compartments. We therefore used Biacore to examine the ability of our 346 
purified bovine FST forms to bind to immobilized HSP. As shown in table 4, isoform #1 347 
(32kDa) and hr FST-288 of the same molecular weight both bound to HSP with similar KD 348 
values (~3nM). However, no quantifiable binding of FST isoforms #2, #3, #4 and #5 to 349 
immobilised HSP was observed. 350 
 351 
 352 
Comparison of biological potencies and FST binding properties of activins A, AB and B 353 
 354 
In terms of their ability to suppress androstenedione secretion in the theca cell bioassay (table 355 
5) activin-A was about two-fold more potent that activin-AB whereas activin B did not elicit a 356 
response at the maximum concentration tested (50 ng/ml). Biacore analysis showed that 357 
activin-AB and activin-B bound to immobilised rh FST-288 with ~2-fold higher affinity than 358 
activin-A (table 5). There were insufficient amounts of purified bovine FST isoforms 359 
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available to carry out a systematic evaluation of their binding affinities for the three different 360 
rh activin isoforms. 361 
 362 
 363 
Analysis of FST and activin isoforms in bFF samples from estrous cycle-synchronized heifers 364 
 365 
As circulating gonadotrophin (LH, FSH) and steroid hormone (E2, P4) profiles and detailed 366 
information on ovarian ultrasonography and intrafollicular E2, P4 and inhibin concentrations 367 
in these heifers have been documented in a previous report (Sunderland et al. 1996) only 368 
new information pertaining to the analysis of FST and activin isoforms in bFF is presented 369 
in this paper (Fig. 5). Preliminary analysis of a subset of pooled bFF samples showed that 370 
activin B concentrations (214±25 ng/ml) were substantially (~20-fold) lower than activin-A 371 
(4333±379 ng/ml) and ~6-fold lower than activin-AB (1259±71 ng/ml) concentrations. 372 
Given the limited bFF sample volumes available it was not feasible to determine activin B 373 
concentrations in this sample set. 374 
 375 
Overall, follicle diameter was positively correlated with E/P ratio (r=0.56; P<0.0001) and 376 
negatively correlated with activin-A (r=-0.34; P=0.003), activin-AB (r=-0.51; P<0.0001) and 377 
‘total’ FST measured by ELISA (r=-0.70; P<0.0001). Using SDS-PAGE/Western blotting 5-6 378 
different FST isoforms were detected in individual bFF samples (apparent Mr: 65, 41, 37, 35, 379 
33 and 31 kDa) representing, on average, 6, 13, 24, 26, 13 and 17%, respectively of total FST 380 
(Fig. 6). Follicle diameter was positively correlated with % abundance of the 41kDa (r=0.59; 381 
P<0.0001) and 35kDa (r=0.29; p=0.014) FST isoform but negatively correlated with % 382 
abundance of the smaller 33kDa (r=-0.56; p<0.0001) and 31 kDa (r=-0.41; p< 0.001) FST 383 
isoforms. There was a particularly marked effect of follicle status on the % abundance of the 384 
33kDa isoform that showed up to a 3-fold difference (P<0.0001) between DF and SF2p 385 
follicles. 386 
 387 
Two-way ANOVA revealed a significant effect of cycle day (P<0.05) and follicle status (P<0.01)  388 
(i.e. DF, SF1, SF2p) on follicle diameter, E/P ratio, activin-A, activin-AB and ‘total’ FST 389 
concentrations (Fig 5). Furthermore, FST concentration was much lower in DF than in SF1 or 390 
SF2p (P<0.05). During growth and selection of the ‘first wave’ follicles in the early luteal 391 
phase (i.e. days 3 to 6) ‘total’ FST, activin-A, activin-AB concentrations decreased in DF 392 
(P<0.05) but were maintained or increased in SF1 and SF2p. During subsequent atresia of DF 393 
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(i.e. days 6 to 12), ‘total’ FST and activin-AB remained lower in DF than in SF1 and SF2p 394 
(Fig. 5). Two-way ANOVA revealed a significant (P<0.05) effect of follicle status (i.e., DF, 395 
SF1, SF2p) on % abundance of the 41, 37, 35, 33 and 31kDa FST isoforms and an effect of 396 
cycle day on % abundance of the 65kDa FST isoform (Fig. 6).  397 
 398 
In ‘follicular phase’ samples (Fig.5), follicle status significantly affected total FST and 399 
activin-AB concentrations, activin/FST ratio and E/P ratio. FST concentration was much 400 
lower in DF than in SF1 or SF2p. There was also a significant effect of cycle day (i.e. pre- 401 
versus post-LH surge) on activin-A, activin-AB and FST levels. Follicle status, but not cycle 402 
day, also affected the % abundance of the 41, 33 and 31kDa FST isoforms (Fig. 6). 403 
 404 
 405 
 406 
Discussion 407 
  408 
It is well established that FST can selectively attenuate signalling by activins and, to a lesser 409 
degree, other ligands belonging to the TGFβ superfamily (e.g. BMP2, BMP4, BMP7, BMP15, 410 
GDF9, myostatin/GDF8) by forming a stable inactive complex with the ligand in the 411 
extracellular compartment thus blocking binding to signalling receptors (Sugino et al. 1993, 412 
Nakamura et al. 1997, Phillips & de Kretser 1998, Chang 2008). However, the existence of 413 
multiple isoforms of FST in biological fluids such as ovarian FF and serum (Robertson 1992, 414 
Sugino et al. 1993, Nakamura et al. 1997, Schneyer et al. 1997, Glister et al. 2006) is 415 
indicative of a more complex scenario, the potential significance of which has yet to be fully 416 
resolved. FST isoforms differ in their ability to bind to proteoglycans on the cell surface and 417 
extracellular matrix with the shorter, carboxy-terminal truncated form (FST-288) showing a 418 
much higher affinity for HSP than the long isoform (FST-315). This reflects the ability of the 419 
carboxy-terminal domain of FST-315 to mask the HSP binding region found within the FS1 420 
domain (Keutmann et al. 2004, Hedger & de Kretser 2013). Activin-binding activity involves 421 
the amino terminal domain, FS1 and FS2 domains (Keutmann et al. 2004, Chang 2008). 422 
Differences in the propensity of FST isoforms to bind to cell surface proteoglycans is 423 
indicative of differential roles in controlling activin distribution and bioavailability at local 424 
and/or distant target tissue levels. 425 
 426 
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In view of substantive evidence implicating the inhibin-activin-FST system in ovarian follicle 427 
development, in this study we devised an effective chromatographic scheme to purify five 428 
native isoforms of FST from bovine ovaries (overall FST yield 17.7%; ~10,000-fold 429 
purification factor) thus permitting a comparison of their biological activities and binding 430 
affinities for activin-A and HSP. We show that all five FST isoforms are capable of blocking 431 
the suppressive effect of activin on androgen secretion by bovine theca cells. The smallest 432 
isoform (bovine #1; 31kDa, deduced to be the non-glycosylated, carboxy-terminal truncated 433 
form, FST-288) represented about 17% of total FST in bFF and was the most bio-potent, 434 
being equipotent with rh FST-288 (31kDa) obtained from a commercial source. It also 435 
exhibited KD values for binding to activin-A and HSP that were very similar to those for rh 436 
FST-288. In contrast, two of the larger isoforms we isolated (35kDa, 41kDa) showed reduced 437 
biopotency (39 and 53% respectively) as well as significantly lower affinity for activin-A and 438 
undetectable binding to HSP. On the basis of their mobility on SDS-PAGE before and after 439 
enzymatic deglycosylation it was deduced that the 35kDa isoform (bovine #3) is non-440 
glycosylated FST-315 while the 41kDa isoform (bovine #5) is its glycosylated counterpart. 441 
Respectively, these FST isoforms represented 26% and 13% of total FST in bFF. The other 442 
two isoforms we purified, bovine #2 (33kDa) and #4 (37kDa) had relative bio-potencies that 443 
were not significantly different from FST-288 (77% and 89%, respectively). The affinity of 444 
the 37kDa isoform for activin-A was ~3-fold less than that of FST-288 and neither the 33kDa 445 
or 37kDa isoform showed detectable binding to HSP. The 33kDa isoform was deduced to be a 446 
non glycosylated variant of FST-303 core protein since no mobility shift occurred upon 447 
deglycosylation. The 33kDa form represented on average 13% of the total FST in bFF 448 
although, as discussed later, it showed a substantial follicle status-dependent variation in vivo 449 
(6-21% of total FST). The chromatographic yield of the 37kDa FST isoform was low (only 450 
12μg recovered) and there was insufficient material to further characterise it by 451 
deglycosylation mobility shift analysis. However, on the basis of previous characterisation of 452 
porcine FST isoforms (Sugino et al. 1993) it is considered likely to be a glycosylated form of 453 
FS-303.  454 
 455 
The native bovine FST isoforms we isolated differed both in their ability to neutralize activin-456 
A bioactivity in vitro and in their binding affinity for activin-A. This observation contrasts 457 
with an early report (Sugino et al. 1993) that different FST isoforms purified from porcine FF 458 
displayed very similar activin binding activities. However, activin binding was estimated 459 
using a polyethyleneglycol precipitation method with 
125
I-labelled activin-A, as opposed to 460 
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direct binding of FST to unlabelled activin-A immobilized on a Biacore sensorchip, as used in 461 
our study. Another study employing the Biacore approach (Hashimoto et al. 2000) reported 462 
that hrFST-288 bound activin-A with an affinity an order of magnitude higher than hrFST-463 
315, a finding in agreement with our comparison of native bovine FST isoforms.  464 
 465 
To our knowledge this is the first report to compare both the bioactivities and FST binding 466 
properties of the three activin isoforms. In terms of their relative bioactivity it has been 467 
reported previously that activin B is much less potent that activin-A in various in vitro 468 
bioassays (Sugino et al. 1997, Schneyer et al. 2003), a finding in agreement with our study 469 
using a bovine theca cell bioassay. Using immobilized hrFST-288 we also found that the 470 
binding affinities for activin-AB and activin-B were significantly higher than for activin-A 471 
and suggest that this could contribute to the higher biopotency of activin-A. However, using a 472 
radioligand binding assay it was reported (Schneyer et al. 2003) that activin-B bound to 473 
hrFST-288 with a lower affinity than activin-A, in disagreement with our finding based on the 474 
Biacore technique. Regardless of this discrepancy, the present study shows that levels of 475 
activin B in bovine follicular fluid are much lower than activin-AB that, in turn, are lower 476 
than activin-A. Collectively, these observations suggest that activin B has a minimal 477 
physiological role(s) in bovine antral stage follicles. 478 
 479 
Evidently, this study is also the first to compare the bioactivities of multiple native FST 480 
isoforms using an homologous (i.e. same species) ovarian bioassay. Many studies have used 481 
FST-dependant inhibition of FSH release from rat anterior pituitary cells as a heterologous 482 
bioassay for purified porcine or bovine FST preparations (Robertson et al. 1987, Sugino et al. 483 
1993, Sugino et al. 1997) with the possibility that species differences could affect the relative 484 
responses observed. In fact, bovine isoform #1, evidently unglycosylated core protein FST-485 
288, behaved identically to hrFS-288 in our bovine theca cell bioassay and had the highest 486 
biopotency of the five FST isoforms purified. Similarly, the activin binding affinity of 487 
isoform #1 was not significantly different to hrFS-288 and was also the highest of the five 488 
isoforms. Moreover, of the different FST preparations tested, only hrFST-288 and bovine 489 
isoform #1 had the ability to bind to heparan sulphate proteoglycan with both exhibiting a 490 
similar KD value of 3-4nM, close to the value reported by Sugino and colleagues (Sugino et 491 
al. 1997) for the binding of porcine FST-288 to granulosa cell membranes (KD 2nM). These 492 
observations support the notion that FST-288 is the most effective of all the isoforms at 493 
neutralising activin-A activity, at least in the present in vitro bioassay. This can arise by a 494 
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two-step mechanism: not only does it bind to activin-A with the greatest affinity, thereby 495 
blocking its interaction with activin signalling receptors, but it also has the greatest propensity 496 
to bind to cell surface associated heparan sulphate proteoglycans, thereby becoming 497 
concentrated on the cell surface to provide an even more effective ‘barrier’ to prevent activin 498 
association with its signalling receptors. In addition, it has been shown that activin: FST 499 
complexes bound to heparan sulphate proteoglycans on the cell surface are endocytosed 500 
leading to their subsequent lysosomal degradation (Hashimoto et al. 1997, Sugino et al. 501 
1997). The KD value we observed for FST-288-activin-A binding was of the same order of 502 
magnitude (low nM range) as that for FST-288-HSP binding indicating stable complex 503 
formation in both cases. In further work it would be of interest to use the Biacore technique to 504 
examine the binding kinetics of ternary complex formation/dissociation (HSP-FST-activin) in 505 
an attempt to model likely interactions at or near the cell surface in vivo. 506 
 507 
We deduce that purified bovine isoforms #3 and #5 are non-glycosylated and glycosylated 508 
variants of core protein FST-315, respectively. They showed the lowest activin biopotencies 509 
of the five isoforms purified, up to 60% less effective at neutralising activin in bioassay 510 
compared to isoform #1 (FST-288). Moreover, their affinity for activin-A was an order of 511 
magnitude less than for isoform #1/FST-288. Although this finding conflicts with a previous 512 
report that different isoforms of porcine FST show similar activin-binding affinities (Sugino 513 
et al. 1993) our finding is in agreement with a later study comparing recombinant human 514 
FST-288 and FST-315 activin-binding affinities (Hashimoto et al. 2000). The explanation for 515 
this discrepancy is not known but, consistent with earlier findings for porcine (Sugino et al. 516 
1993, Sugino et al. 1997), the larger isoforms of bovine FST we isolated displayed much 517 
lower (non-quantifiable) binding to HSP. 518 
 519 
Having examined the biological activities, activin-binding and HSP-binding properties of the 520 
different naturally occurring FST isoforms purified from bovine ovaries, we asked the 521 
question: do their relative intrafollicular expression levels vary during bovine follicle 522 
development in vivo? To address this we used a quantitative immunoblotting approach to 523 
analyse individual bFF samples harvested from the follicles of oestrous cycle-synchronized 524 
cattle that had been ovariectomized at five key stages of follicle ‘wave’ development 525 
(Sunderland et al. 1996). Additionally, we used a panel of specific 2-site immunoassays to 526 
quantify ‘total’ FST, activin-A and activin-AB concentrations in the same samples; attempts 527 
to quantify activin B in individual samples using a new immunoassay (Ludlow et al. 2009) 528 
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were unsuccessful due to the much lower concentration present and the insufficient sample 529 
volumes available. Concentrations of activin-A were around 3-fold higher than activin-AB 530 
and estimated to be at least 20-fold higher than activin-B levels, indicating a minimal 531 
physiological role for activin-B in the bovine antral follicle.   532 
 533 
Although interpretation of the resultant dataset is complex owing to the number of different 534 
analytes, time-points and follicle status categories involved, the findings are broadly 535 
consistent with those of an earlier study involving analysis of size-ranked follicles from the 536 
ovaries of randomly cycling cattle obtained from an abattoir (Glister et al. 2006). In 537 
particular, total FST levels in bFF were inversely related to follicle diameter and E/P ratio in 538 
both studies. Likewise, the average proportion of total FST represented by each different 539 
isoform was very similar in both studies. FST-288 core protein represented about 17% of total 540 
FST while  glycosylated/nonglycosylated forms of the carboxy-terminal extended core 541 
proteins FST-303 and FST-315 represented 13/24% and 26/13% respectively. The relatively 542 
low abundance of FST-288 present in bFF is still much higher than the estimate of 1% 543 
reported for porcine FF (Inouye et al. 1991) suggesting a pronounced species variation. A low 544 
abundance of FST-288 present in FF most likely reflects its high affinity for HSP that would 545 
result in its adhesion to the plasma membrane of granulosa cells lining the follicular antrum 546 
and cumulus cells surrounding the oocyte. By contrast, FST-303 and FST-315 would tend to 547 
remain in the liquid phase, likely diffusing further from their site of secretion (granulosa cells) 548 
to sequester activins and other TGFβ family ligands arising from other intra- or extra-ovarian 549 
sources, and perhaps acting as an ‘activin reservoir’. Interestingly, while each FST isoform 550 
showed some variation in relation to follicle status and stage of cycle, the 33kDa isoform 551 
(deduced to be FST-303 core protein) showed the greatest difference in relative abundance 552 
between dominant and subordinate follicles, being up to 3-fold higher in the latter. Whilst the 553 
explanation and/or physiological significance of this intriguing observation remains obscure it 554 
is speculated that dominant follicles may show decreased expression of a specific protease 555 
that cleaves FST-315 into FST-303 (Welt et al. 2002). Consistent with this suggestion, the 556 
abundance of the 41kDa and 35kDa isoforms (glycosylated/nonglycosylated FST-315) tended 557 
to show the reverse pattern to FST-303, being highest in dominant follicles. The nature of the 558 
65kDa band representing about 6% of immunoreactive FST detected by immunoblotting in 559 
bovine FF remains unknown since it was not one of the isoforms purified in the present study. 560 
 561 
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Regarding the physiological interpretation of these data, on days 0, 1 and 6 of the cycle (see 562 
Fig. 5) the  “selected” healthy DF was clearly distinguished from atretic SFs that were smaller 563 
and had lower E/P ratio, but higher total FST (and 33kDa, 31kDa FST forms), activin-A and 564 
activin-AB. These findings imply that high FST and activin levels may hinder growth and E 565 
production of SFs, which is critical for onset of follicle dominance. This idea is supported by 566 
the change in FST and activin levels from Day 3 (before selection) to Day 6 (when DF is 567 
present) when levels of total FST (and 33 kDa and 37 kDa FSH isoforms) and activin-A and -568 
AB decrease as the size and E/P ratio increase in the DF. Moreover, on Day 3 before onset of 569 
dominance, when DF and SF showed a similar size and E:P ratio, total FST (and most FST 570 
isoforms) and activin levels remained similar between follicle types. From Days 6 to 12 as the 571 
DF from Day 6 became atretic, as indicated by its greatly reduced E/P ratio, its diameter and 572 
total FST, activin-A and –AB levels remained unchanged. However, the relative abundance of 573 
several FST isoforms (31kDa, 37kDa) increased as the DF from Day 6 became atretic whilst 574 
other isoforms (35kDa, 41kDa, 65kDa) showed a corresponding decrease.  The interpretation 575 
of this intriguing observation remains unknown but, overall, the above findings imply that 576 
other factors (like inhibin) may be critical for loss of non-ovulatory DF function.  577 
 578 
Expression and secretion of FST by granulosa cells has been shown to be upregulated by FSH 579 
and IGF1 (Klein et al. 1991, Lindsell et al. 1994, Glister et al. 2001, Glister et al. 2003, 580 
Glister et al. 2006). However, the relative abundance of different FST isoforms secreted by 581 
cultured bovine granulosa cells was found to be very similar under basal, FSH- and IGF1-582 
stimulated conditions (Glister et al. 2006) making it difficult to relate the present changes in 583 
intrafollicular FST isoform profiles to presumptive changes in FSH and/or IGF action 584 
occurring in vivo. Expression of FST by granulosa cells is also upregulated by activin (Michel 585 
et al. 1992, Fazzini et al. 2006) but whether activin affects the FST isoform distribution 586 
pattern is not known. Intrafollicular levels of activin-A, activin-AB and ‘total’ FST followed a 587 
similar pattern of change in the present study being lowest in dominant follicles at all cycle 588 
stages examined with the exception of day 3. For the most part, the mass ratio of ‘total’ 589 
activins (i.e. activin-A+AB) to FST levels was maintained around 1:1 at all follicle stages 590 
examined, consistent with FST-activin complex formation and at least partial neutralization of 591 
activin signalling in accordance with the 2:1 binding stochiometry (Shimonaka et al. 1991, 592 
Welt et al. 2002, Chang 2008). This apparent lack of saturation of activin’s FST binding 593 
capacity implies that the bioavailability of other locally expressed TGFβ ligands capable of 594 
binding FST, such as BMP-2, -4, -7 and GDF9, may by modulated by intrafollicular FST. An 595 
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important caveat is that levels of activins and FST in bFF may provide little indication of their 596 
relative concentrations and interactions at or near the cell surface. The challenge remains to 597 
devise experimental approaches to address this issue. 598 
 599 
In conclusion we have shown that activin-A and –B as well as naturally occurring isoforms of 600 
bovine ovarian FST that differ in their biological activity, binding affinities for activin and 601 
cell surface proteoglycans, display follicle status-dependent differences in their intrafollicular 602 
abundance during the bovine oestrous cycle. Given the prominent autocrine/paracrine 603 
regulatory roles that activins and other TGFβ superfamily members are thought to engage in 604 
throughout folliculogenesis, these findings underscore the inherent complexity and 605 
multifactorial nature of this system. Further research is needed to delineate the biological 606 
significance of multiple FST isoforms as extracellular modulators of signalling by activins 607 
and, likely, other TGFβ family members secreted by the oocyte, granulosa and/or theca cells. 608 
 609 
 610 
Declaration of Interest 611 
 612 
The authors declare that there is no conflict of interest that would prejudice the impartiality of 613 
this scientific work 614 
 615 
 616 
Funding 617 
 618 
This work was primarily supported by the Biotechnology and Biological Sciences Research 619 
Council (grants 45/S14995 and BB/G017174/1 to P.G.K). The in vivo study that generated 620 
the set of bovine follicular fluid samples analysed here was supported by grants from 621 
University College Dublin, BioResearch Ireland, and the US-Ireland Agricultural Exchange to 622 
SJS; USDA grants 88-37240-4104 and 90-37240-5508, subcontract from NICHD grant U54 623 
HD29164, and Research Excellence Funds from Michigan State University to J.J.I. 624 
 625 
 626 
Acknowledgements 627 
 628 
 20 
The authors thank Prof NP Groome (Oxford Brookes University, UK) for providing 629 
monoclonal antibodies against FST and activins, Dr A Parlow (NHPP, Torrance, CA, USA) 630 
for supplying ovine LH and recombinant human FST used to calibrate the FST ELISA, 631 
NIBSC for recombinant human activin-A standard used to calibrate the activin-A ELISA and 632 
Prof H Sugino (University of Tokushima, Japan) for providing porcine activin-AB used to 633 
calibrate the activin-AB ELISA. We are grateful to Dr CF Kemp for assistance with the 634 
Biacore experiments. 635 
 636 
Table 1. Estimates of the molecular weight and relative purity of the five follistatin 637 
isoforms isolated from bovine follicular fluid 638 
Purified 
Follistatin 
isoform 
Apparent 
molecular 
weight 
(kDa) 
Total Yield 
(based on 
A280nm) 
(μg) 
Purity 
(Western 
blot) 
(%) 
Purity 
(Coomassie 
-stained gel) 
(%) 
Purity 
(Follistatin 
ELISA) 
(%) 
Bovine #1 31 93 83 92 93 
Bovine #2 33 53 75 82 85 
Bovine #3 35 55 85 79 79 
Bovine #4 37 12 74 88 ~100 
Bovine #5 41 19 75 82 95 
 639 
 640 
 641 
Table 2. Purification table for bovine follistatin isoforms  642 
Fraction Total Protein
a
 
(mg) 
Follistatin
b
 
(μg) 
Purification 
(-fold) 
Recovery 
(%) 
bFF 
(start material) 
13,000 1,164 1 100 
Immunoaffinity 
eluate 
3.28 733 2,497 63 
  Anion exchange 
Non-retained # nd 127.4 nd 10.95 
Peak A nd 24.3 nd 2.08 
Peak B nd 110.9 nd 9.53 
Peak C nd 25.4 nd 2.18 
Peak D nd 115.9 nd 9.97 
Total nd 403.9 nd 34.7 
   RP-HPLC 
Bovine #1 0.093 86.6 10,400 7.44 
Bovine #2 0.053 45.3 9,553 3.89 
Bovine #3 0.055 43.4 8,810 3.73 
Bovine #4 0.012 12.3 11,475 1.06 
Bovine #5 0.019 18.0 10,721 1.55 
Total  (#1 - #5) 0.232 205.6 10,191 17.7 
a 
based on absorbance at 280nm; 
b
based on follistatin ELISA; nd, not determined 643 
 644 
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 645 
 646 
Table 3. Comparison of biological potencies of the five isoforms of follistatin isolated from 647 
bovine follicular fluid with that of human recombinant follistatin 288 648 
Follistatin 
 isoform 
Molecular weight 
(kDa) 
Mean IC50 in bioassay 
(FST:Activin ratio) 
Relative biopotency 
(%) 
hrFST-288 31 1.7 100 
Bovine #1 31 1.7 100 
Bovine #2 33 2.2 77 
Bovine #3 35 4.4 39 
Bovine #4 37 1.9 89 
Bovine #5 41 3.2 53 
 649 
 650 
Table 4. Comparison of activin-A-binding and heparin sulphate proteoglycan (HSP)-651 
binding properties of five isoforms of follistatin isolated from bovine follicular fluid 652 
Follistatin 
isoform 
Molecular 
Weight 
(kDa) 
KD  (Activin-A) 
(nM) 
KD (HSP) 
(nM) 
hrFST-288 31 1.8±0.61
ab
 3.93±0.57
a
 
Bovine #1 31 1.6±0.16
 a
 2.94±1.36
a
 
Bovine #2 33  2.9±0.30
 ab
 nd 
Bovine #3 35 33.2±13.9
c
 nd 
Bovine #4 37 4.4±1.48
b
 nd 
Bovine #5 41 34.3±4.14
c
 nd 
p-value (ANOVA) <0.001 0.24 
nd:  not determined as binding too low to quantify 653 
 654 
 655 
Table 5. Comparison of follistatin
•
-binding properties and biological potencies (bovine 656 
theca cell bioassay) of three recombinant human activin isoforms 657 
Activin isoform KD (FST) 
(nM) 
Bioassay IC50  
(ng/ml) 
Activin-A 0.36±0.02
a
 7.3±2.7
a
 
Activin-AB 0.15±0.01
b
 14.7±7.8
a
 
Activin-B 0.14±0.01
b
 >50
b 
(NR) 
p-value (ANOVA)  <0.01 <0.01 
•
recombinant human FST-288 658 
NR, no detectable response at 50ng/ml 659 
 660 
 661 
 662 
 663 
 664 
 665 
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 666 
Figure Legends 667 
 668 
Fig. 1 SDS-PAGE/western blotting analysis of chromatographic fractions generated during 669 
purification of FST isoforms from bovine follicular fluid (bFF). Samples were 670 
electrophoresed under non-reducing conditions using 12.5% acrylamide gels. In A proteins 671 
were transferred to nitrocellulose membrane and immunostained with FST antibody; in B the 672 
gel was directly stained for total protein using coomassie blue.  673 
 674 
Fig. 2  Elution profile (absorbance at 280nm) for the anion exchange FPLC step after 675 
applying the highly-enriched fraction from the FST immunoaffinity column.  676 
 677 
Fig. 3 SDS/PAGE analysis of four purified bovine FST isoforms before (-) and after (+) 678 
enzymatic deglycosylation.  Samples were electrophoresed under non-reducing conditions 679 
using 12.5% acrylamide gels and total protein was detected by silver-staining. Lanes 1-2 680 
show the behaviour of the control protein (Fetuin) supplied with the deglycosylation kit. 681 
 682 
Fig. 4 Panel A: Comparison of the bio-potencies of the five purified isoforms of bovine FST 683 
and rh FST-288 in reversing the activin-A-induced suppression of androstenedione secretion 684 
by bovine theca cells in vitro. Panel B shows that none of the FST preparations affected 685 
‘basal’ androstenedione secretion by cells cultured in the absence of activin-A. 686 
 687 
Fig. 5 Changes in follicle diameter and E/P ratio, activin-A, activin-AB, combined activin-688 
A/-AB and total FST concentrations in follicular fluid obtained from cattle (n=28) 689 
ovariectomized at five time-points during a synchronized estrous cycle. The horizontal bar 690 
beneath the x-axis distinguishes the follicular phase (FP) from the luteal phase (LP). Values 691 
are means ±SEM and results of 2-way ANOVA are indicated on each panel. 692 
 693 
Fig. 6 Changes in the relative abundance (%) of six different Mr isoforms of FST in 694 
follicular fluid obtained from cattle (n=28) ovariectomized at five time-points during a 695 
synchronized estrous cycle. The horizontal bar beneath the x-axis distinguishes the follicular 696 
phase (FP) from the luteal phase (LP). Values are means ±SEM and results of 2-way ANOVA 697 
are indicated on each panel. 698 
 699 
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